13 / 46
4
t h
E u r o S c i C o n C o n f e r e n c e o n
Neurology & Neurological
Disorders
Neurology 2018
J u l y 1 2 - 1 3 , 2 0 1 8
P a r i s , F r a n c e
Page 75
Journal of Neurology and Neuroscience
ISSN: 2171-6625
Aim:
The aim of the study was to review the quality of life of the patients with
daily chronic headache (CDH) and determine the effectiveness of Botulinum
toxin type A (BTA) influence on improving the quality of life by reducing the
daily headache.
Material & Methods:
54 patients, from both sexes, with a minimum age of 18
years old were studied. The inclusion criteria were the presence of primary
daily chronic headache with more than 4-hour duration, a frequency of 15 days
or more monthly, in the last three months and disease duration of 3 years for
the treatment of CDH using BTA. The study involved 54 patients, of whom
where 31 women and 23 men with an average age of 42 years. The patient’s
condition was evaluated on the third day, on the 7th day and on the 15th day
after the BTA injection and assessed every 15 days for 3 months. The efficacy
of BTA was evaluated by several measurements of VAS (Visual Analog Scale),
Headache Intake Questionnaire: HSQoLQ (Headache Specific Quality of Life
Questionnaire), HMQ (Headache Management Questionnaire), HDQ (Headache
Disability Questionnaire).
Results:
After 3 months 2 (4%) patients had no changes, 7 (13%) patients with
less than 50 percent reduction in pain, 23 (43%) reported 70 to 95 percent pain
relief, and 22 (40%) had complete relief.
Conclusion:
The work presented here has profound implications for future
studies of BTA injections for patients with CDH. The obtained results testify
to an improvement in the quality of life of patients with CDH against the
background of injections of BTA.
Biography
Kadyrkhodjayeva Nigora has finished her study at the Tashkent
Medical Academy in 2006. After that, she was studying
Psychiatry and Psychotherapeutics from 2006 till 2007 at the
Tashkent Institute of Postgraduate Medical Education. She was
trained in Neurology at the Tashkent Institute of Postgraduate
Medical Education 2007-2009. She has been practicing as a
Neurologist since 2009. She passed Clinical attachment in
Neurology Department of Rashid Hospital, Dubai, UAE. She
has valid practice license from UAE. She successfully cleared
certification course of BLS & ACLS in 2018. From September
2017, she is pursuing her PhD at the Tashkent Medical
Academy. She has published 3 articles in reputed journals and
several articles, abstracts in local journals.
kadyrkhodjayeva@hotmail.comNigora Kadyrkhodjayeva and Anna Prokhorova
Tashkent Medical Academy, Uzbekistan
Nigora Kadyrkhodjayeva et al., J Neurol Neurosci 2018, Volume: 9
DOI: 10.21767/2171-6625-C1-009
Optimization of management of primary chronic headache with
the use of Botulotoxin A